Runben Biotechnology (603193) Fundamentals 2026 — P/E 24.2x, Revenue Analysis | SniperIQ
Runben Biotechnology (603193) is a CN-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ¥7.8B, trading at ¥19.37 on the SHH. This SniperIQ fundamentals page covers Runben Biotechnology's valuation (P/E 24.2x, P/B 3.4x), profitability (net margin 20.5%), revenue (¥1.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Runben Biotechnology's market cap?
Runben Biotechnology (603193) has a market capitalization of approximately ¥7.8B, trading at ¥19.37 on the SHH. Market cap moves with the live share price.
What is Runben Biotechnology's P/E ratio?
Runben Biotechnology's trailing twelve-month P/E ratio is 24.2x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Runben Biotechnology?
Runben Biotechnology runs a net profit margin of 20.5%, a gross margin of 58.5%, and an operating margin of 23.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Runben Biotechnology generate?
Runben Biotechnology reported revenue of ¥1.5B for fiscal year 2025, with net income of ¥315M and earnings per share (EPS) of 0.78. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Runben Biotechnology pay a dividend?
Runben Biotechnology offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Runben Biotechnology financially healthy?
Runben Biotechnology carries a debt-to-equity ratio of 0.00x and a current ratio of 10.98x, with a market beta of 0.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Runben Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Runben Biotechnology (603193) the key facts are: market cap ¥7.8B, P/E 24.2x, revenue ¥1.5B, 52-week range 17.77-37.15. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Runben Biotechnology's full fundamentals live
Get Runben Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.